INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
2.330
+0.150 (6.88%)
At close: Sep 18, 2026, 4:00 PM EDT
2.341
+0.011 (0.46%)
After-hours: Sep 18, 2026, 7:30 PM EDT
INmune Bio Employees
INmune Bio had 21 employees as of December 31, 2025. The number of employees decreased by 1 or -4.55% compared to the previous year.
Employees
21
Change (1Y)
-1
Growth (1Y)
-4.55%
Revenue / Employee
n/a
Profits / Employee
-$876,952
Market Cap
64.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 21 | -1 | -4.55% | 21 | 0 |
| Dec 31, 2024 | 22 | 5 | 29.41% | 13 | 9 |
| Dec 31, 2023 | 17 | 7 | 70.00% | 11 | 6 |
| Dec 31, 2022 | 10 | 0 | - | 10 | 0 |
| Dec 31, 2021 | 10 | 5 | 100.00% | 10 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Gossamer Bio | 162 |
| Alps Group | 93 |
| XBiotech | 87 |
| MindWalk Holdings | 77 |
| Pliant Therapeutics | 49 |
| Boundless Bio | 28 |
| Spero Therapeutics | 25 |
| LeonaBio | 19 |
INMB News
- 5 days ago - INmune Bio Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 5 days ago - INmune Bio Appoints Sanofi Rare-Disease Executive and Biopharma Business Development Leader to Board - GlobeNewsWire
- 10 days ago - INmune Bio to Present at the H.C. Wainwright Global Investment Conference - GlobeNewsWire
- 24 days ago - INmune Bio submits two regulatory packages to EMA for Ebstrocel - TheFly
- 24 days ago - INmune Bio Advances Ebstrocel™ Toward European Marketing Authorization with EMA Regulatory Filings - GlobeNewsWire
- 6 weeks ago - INmune Bio Earnings Call Transcript: Q2 2026 - Transcripts
- 6 weeks ago - INmune Bio Quarterly report: Q2 2026 - Filings
- 6 weeks ago - INmune Bio Earnings release: Q2 2026 - Filings